A5021945411- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Urinary and Genital Oncology Studies
- IL-33, ST2, and ILC Pathways
- Eosinophilic Disorders and Syndromes
- Gut microbiota and health
- Testicular diseases and treatments
- Pain Management and Opioid Use
- Pharmacological Effects and Toxicity Studies
- Kidney Stones and Urolithiasis Treatments
- Renal cell carcinoma treatment
- Antibiotics Pharmacokinetics and Efficacy
- Salmonella and Campylobacter epidemiology
- Urologic and reproductive health conditions
- Inflammatory Biomarkers in Disease Prognosis
- Sperm and Testicular Function
- Esophageal Cancer Research and Treatment
- Economic and Financial Impacts of Cancer
- Cancer, Hypoxia, and Metabolism
- Augmented Reality Applications
- Occupational and environmental lung diseases
- Surgical Simulation and Training
- Opioid Use Disorder Treatment
- Immune Cell Function and Interaction
- Adrenal and Paraganglionic Tumors
Nagoya City University
2021-2024
Hamamatsu University School of Medicine
2024
Anjo Kosei Hospital
2024
Ipilimumab and nivolumab treatment against advanced metastatic renal cell carcinoma (RCC) causes severe lethal immune-related adverse events (irAEs). Predicting irAEs might improve clinical outcomes, however no practical biomarkers exist. This study examined whether eosinophils could be effective for ≥grade 2 in RCC.We retrospectively analyzed 75 patients with RCC treated ipilimumab between August 2018 March 2021 a multicenter study. Eosinophils were before weeks after treatment, immediately...
Introduction: The training box is an effective tool used by surgical trainees. Suturing the common method of practicing laparoscopic surgery; however, cost needles and threads for long-term practice remains a problem. In this study, we incorporated original Japanese surgery making origami paper crane (laparoscopic (LOT)) evaluated its effect on clinical results as practice. Methods: LOT was performed using single 7.5 × cm in surgery. bench-top total time required to make one measured...
To identify biomarkers associated with the effectiveness of ipilimumab plus nivolumab against advanced metastatic renal cell carcinoma.We retrospectively analyzed data 75 patients treated at seven hospitals between August 2018 and April 2021. Prognostic were assessed prior to initiating treatment nivolumab. Median overall survival progression-free examined using Kaplan-Meier method. Univariate multivariate analyses performed predictors disease progression. The International Metastatic Renal...
Pembrolizumab, an anti-programmed death-1 specific monoclonal antibody is a second-line treatment for metastatic urothelial carcinoma. Physicians should be aware of adverse immune-related events associated with the use immune checkpoint inhibitors, particularly adrenocortical insufficiency, which poses risk death. We report case secondary insufficiency due to isolated adrenocorticotropic hormone deficiency empty sella syndrome after pembrolizumab in patient renal pelvic cancer. Fortunately,...
Objectives In March 2019, cefazolin was unavailable owing to difficulty in procuring the active ingredient. Furthermore, supply of alternative drugs, such as cefotiam and cefmetazole, limited. Department Nephro‐Urology, fosfomycin‐based drugs are used substitutes for cefazolin, which is a perioperative prophylactic antibacterial drug. Herein, we investigated effectiveness fosfomycin sodium preventing infection after endoscopic combined intrarenal surgery retrospective preliminary study....
Abstract We elucidated the efficacy of gut microbiome–altering drugs on pembrolizumab in patients with metastatic urothelial carcinoma (mUC). Clinical data were analyzed retrospectively from 133 mUC who received second-line therapy between January 2018 and 2021, following failed platinum-based chemotherapy. evaluated effects (proton pump inhibitors [PPI]/potassium-competitive acid blockers [P-CAB], H2 blockers, antibiotics, non-steroidal anti-inflammatory [NSAIDs], metformin, antipsychotics,...
Introduction The prognosis of adrenal metastasis from non‐small cell lung cancer is very poor. A recent report described the efficacy surgical removal when solitary. However, metachronous bilateral extremely rare, and a treatment strategy has not been established. Case presentation Herein, we describe 52‐year‐old Asian male who presented with right 8 months after immunochemotherapy resection lung. He underwent combined systemic laparoscopic adrenalectomy; however, 9 months, left emerged....
Introduction In Western countries, the risk of a testicular germ cell tumor in men with male factor infertility is greater than general population. However, Japanese data on this are lacking. Additionally, clinical course for pathogenesis involved has not been clearly characterized. Case presentation A 35‐year‐old underwent right orchiectomy because mass his scrotum. He had previous history microdissection sperm extraction undertaken 6 years ago. The final diagnosis scrotal was stage I...
<b><i>Introduction:</i></b> This study had two objectives: (i) to evaluate oncological outcomes in a long-term follow-up of patients with bladder cancer after reduced-port laparoscopic radical cystectomy (RP-LRC) and (ii) assess the effect modified Glasgow prognostic scores (mGPS) on patient outcomes. <b><i>Methods:</i></b> Consecutive (<i>n</i> = 100) who received RP-LRC between March 2012 December 2018 at our institution...
You have accessJournal of UrologyCME1 Apr 2023MP22-04 MAINTENANCE OF SKELETAL MUSCLES WHEN RECEIVING NEOADJUVANT CHEMOTHERAPY IMPROVES THE PROGNOSIS FOR PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER Maria Aoki, Taku Naiki, Toshiharu Morikawa, Teruki Isobe, Masakazu Gonda, Nami Tomiyama, Nagoya, Japan, Nobuhiko Shimizu, Yusuke Noda, Takashi Nagai, Rika Banno, Satoshi Nozaki, Toshiki Etani, Ryosuke Ando, Noriyasu Kawai, and Takahiro Yasui AokiMaria Aoki More articles by this author , NaikiTaku...
You have accessJournal of UrologyCME1 May 2022MP03-18 CHRONOLOGICAL TRANSITION IN OUTCOME OF SECOND-LINE TREATMENT PATIENTS WITH METASTATIC UROTHELIAL CANCER AFTER PEMBROLIZUMAB USAGE: A MULTICENTER ANALYSIS Teruki Isobe, Taku Naiki, Yosuke Sugiyama, Aya Takashi Nagai, Toshiki Etani, Satoshi Nozaki, Keitaro Iida, Yusuke Noda, Nobuhiko Shimizu, Nami Tomiyama, Rika Banno, Hiroki Kubota, Shuzo Hamamoto, Ryosuke Ando, Noriyasu Kawai, and Takahiro Yasui IsobeTeruki Isobe More articles by this...
Abstract Purpose: Ipilimumab and nivolumab treatment against advanced metastatic renal cell carcinoma (RCC) causes severe lethal immune-related adverse events (irAEs). Predicting irAEs might improve clinical outcomes, however no practical biomarkers exist. This study examined whether eosinophils could be effective for in RCC. Methods: We retrospectively analyzed 75 patients with RCC treated ipilimumab between August 2018 March 2021 a multicenter study. Eosinophils were before two weeks after...
Abstract Ipilimumab and nivolumab treatment against advanced metastatic renal cell carcinoma (RCC) cause severe lethal immune-related adverse events (irAEs). Predicting irAEs might improve clinical outcomes, however no practical biomarkers exist. This study examined whether eosinophils could be effective for in RCC. We retrospectively analyzed 75 patients with RCC treated ipilimumab between August 2018 March 2021 a multicenter study. The median overall progression-free survival of who...
The number of patients with cancer and end-stage renal disease is increasing because the success hemodialysis treatment. However, methods for monitoring opioids to control severe pain induced by remain unsatisfactory. A 72-year-old male, a history diabetic nephropathy 16 years prostate three years, was diagnosed metastasis in his 12th thoracic 2nd lumbar vertebrae, treated analgesic management (oxycodone, acetaminophen, pregabalin) radiotherapy. Concern about poor instability blood opioid...
Abstract Background We elucidated the efficacy of gut microbiome–altering drugs on pembrolizumab in patients with metastatic urothelial carcinoma (mUC). Methods Clinical data were analyzed retrospectively from 135 mUC who received second-line therapy between January 2018 and 2021, following failed platinum-based chemotherapy. evaluated effects (proton pump inhibitors [PPI]/potassium-competitive acid blockers [P-CAB], H2 blockers, antibiotics, non-steroidal anti-inflammatory [NSAIDs],...